Neurogene Inc (NGNE) - News Archive

Neurogene Advances Gene Therapy for Rare Neurological Conditions: Pivotal Trial for Rett Syndrome Begins In a significant milestone for the field of gene therapy, Neurogene Inc., a clinical-stage company dedicated to de...

: Neurogene Inc. has reported its financial performance for the second quarter of 2025, marked by significant advancements in its ongoing clinical programs, particularly concerning Rett syndrome. As a burgeoning leader...

Innovative Strides: Neurogene Reports Q1 2025 Financial Results & Progress on Rett Syndrome Gene Therapy A Mission to Transform Neurological Care In a bid to revolutionize the treatment landscape for rare neurological d...

Neurogene Inc. an innovative player within the realm of gene therapy, is poised to make significant strides in the management and treatment of rare complications associated with high-dose gene therapy. During the upcomi...

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates In an era where the convergence of cutting-edge science and innovative business models is reshaping the landscape of biotechnology, Ne...

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome In a significant era for genetic medicine, Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotech company focused on addressing the nee...

In a significant milestone for pediatric neurology, Neurogene Inc. has announced positive interim efficacy data from the first four low-dose participants in its NGN-401 gene therapy clinical trial for Rett syndrome. Thi...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology firm dedicated to developing transformative genetic therapies for rare neurological disorders, reported its second-quarter financial results for 2024, highli...

: Neurogene Inc., a clinical-stage biotechnology company focused on developing genetic therapies for rare neurological diseases, has made significant strides in its NGN-401 gene therapy program for Rett syndrome. Recent...

CSIMarket.com is pleased to feature Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company committed to developing life-changing genetic treatments for families and patients afflicted by rare neurological diseases. Neu...

Neurogene Inc., a clinical-stage company dedicated to developing genetic medicines for rare neurological diseases, has recently reported significant progress in its NGN-401 gene therapy program for Rett syndrome. The co...

Neurogene Inc., a clinical-stage company dedicated to developing groundbreaking genetic medicines for individuals and families affected by rare neurological diseases, has recently announced significant developments in i...

Neurogene Inc. Reports Promising Financial Results and Progress in Genetic Medicine Development for Rare Neurological DiseasesIn a recent press release, Neurogene Inc., a clinical-stage company focused on providing grou...

In recent years, the field of gene therapy has shown great promise in revolutionizing treatment options for patients and families affected by rare neurological diseases. Neurogene Inc., a leading clinical-stage company...

Neurogene Inc., a clinical-stage company dedicated to developing transformative genetic therapies for individuals and families affected by rare neurological disorders, has recently shared its impressive first-quarter 20...

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingNeurogene Inc., a pioneering clinical-stage company focused on developing life-changing...

Neurogene Inc., a clinical-stage genetic medicines company listed on Nasdaq (NGNE), has announced plans to present initial safety and tolerability data gained from its ongoing Phase 1/2 gene therapy clinical trial for p...

Expanding Horizons: Accelerated Enrollment and Promising Breakthroughs in Rett Syndrome Gene Therapy Clinical TrialNeurogene Inc., a pioneering clinical-stage company dedicated to ushering in transformative genetic medi...

Breaking Boundaries in Rare Neurological Disease Treatment: Neurogene Welcomes Dr. Julie Jordan as Chief Medical OfficerNeurogene Inc. (NASDAQ: NGNE), a pioneering clinical-stage company dedicated to transforming the li...